ITGA11

Summary

ITGA11 (integrin subunit alpha 11, HGNC:6136) is a protein-coding gene on chromosome 15q23, encoding Integrin alpha-11 (Q9UKX5). Integrin alpha-11/beta-1 is a receptor for collagen.

This gene encodes an alpha integrin. Integrins are heterodimeric integral membrane proteins composed of an alpha chain and a beta chain. This protein contains an I domain, is expressed in muscle tissue, dimerizes with beta 1 integrin in vitro, and appears to bind collagen in this form. Therefore, the protein may be involved in attaching muscle tissue to the extracellular matrix. Alternative transcriptional splice variants have been found for this gene, but their biological validity is not determined.

Source: NCBI Gene 22801 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 233 total
• Druggable target: yes
• MANE Select transcript: NM_001004439

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6136
Approved symbol	ITGA11
Name	integrin subunit alpha 11
Location	15q23
Locus type	gene with protein product
Status	Approved
Aliases	HsT18964
Ensembl gene	ENSG00000137809
Ensembl biotype	protein_coding
OMIM	604789
Entrez	22801

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 4 protein_coding, 3 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000315757, ENST00000423218, ENST00000562826, ENST00000565868, ENST00000566429, ENST00000568677, ENST00000569346, ENST00000902076, ENST00000902077

RefSeq mRNA: 1 — MANE Select: NM_001004439 NM_001004439

CCDS: CCDS45291

Canonical transcript exons

ENST00000315757 — 30 exons

Exon	Start	End
ENSE00000931668	68350617	68350782
ENSE00000931669	68351258	68351402
ENSE00000942594	68335697	68335845
ENSE00000942597	68330981	68331111
ENSE00000942598	68328096	68328262
ENSE00000942599	68326654	68326796
ENSE00000942600	68325131	68325241
ENSE00000942601	68321418	68321503
ENSE00000942602	68320185	68320392
ENSE00000942603	68317265	68317363
ENSE00000942604	68315651	68315727
ENSE00000942605	68313779	68313868
ENSE00000942606	68312773	68312863
ENSE00000942607	68311290	68311403
ENSE00000942608	68310994	68311080
ENSE00000942609	68307586	68307696
ENSE00000942610	68307348	68307443
ENSE00000942611	68303772	68303885
ENSE00001027007	68369184	68369284
ENSE00001291516	68296532	68303130
ENSE00001297847	68402918	68403029
ENSE00002519031	68348830	68348900
ENSE00003465113	68332338	68332478
ENSE00003480261	68357151	68357299
ENSE00003504022	68358458	68358585
ENSE00003515460	68364707	68364798
ENSE00003669827	68331859	68332062
ENSE00003672575	68361590	68361704
ENSE00003689623	68339500	68339644
ENSE00003847613	68432015	68432163

Expression profiles

Bgee: expression breadth ubiquitous, 180 present calls, max score 96.89.

FANTOM5 (CAGE): breadth broad, TPM avg 25.4645 / max 1405.8718, expressed in 897 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
150661	22.1133	856
150662	1.8502	504
150663	1.0414	349
150653	0.3215	150
150651	0.1381	63

Top tissues by expression

248 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
descending thoracic aorta	UBERON:0002345	96.89	gold quality
thoracic aorta	UBERON:0001515	96.32	gold quality
ascending aorta	UBERON:0001496	96.23	gold quality
calcaneal tendon	UBERON:0003701	92.56	gold quality
stromal cell of endometrium	CL:0002255	91.38	gold quality
body of uterus	UBERON:0009853	91.23	gold quality
aorta	UBERON:0000947	91.02	gold quality
right coronary artery	UBERON:0001625	90.34	gold quality
smooth muscle tissue	UBERON:0001135	89.53	gold quality
myometrium	UBERON:0001296	88.15	gold quality
tendon	UBERON:0000043	87.34	gold quality
left coronary artery	UBERON:0001626	87.21	gold quality
popliteal artery	UBERON:0002250	87.12	gold quality
coronary artery	UBERON:0001621	87.10	gold quality
tibial artery	UBERON:0007610	87.06	gold quality
left ventricle myocardium	UBERON:0006566	86.78	gold quality
upper arm skin	UBERON:0004263	85.56	gold quality
kidney epithelium	UBERON:0004819	85.16	gold quality
endocervix	UBERON:0000458	84.55	gold quality
tendon of biceps brachii	UBERON:0008188	84.35	gold quality
tibia	UBERON:0000979	83.20	gold quality
cardiac atrium	UBERON:0002081	83.17	gold quality
right atrium auricular region	UBERON:0006631	83.08	gold quality
uterine cervix	UBERON:0000002	81.59	gold quality
left uterine tube	UBERON:0001303	81.38	gold quality
heart	UBERON:0000948	81.01	gold quality
sperm	CL:0000019	81.00	gold quality
ectocervix	UBERON:0012249	80.03	gold quality
epithelial cell of pancreas	CL:0000083	79.85	gold quality
heart left ventricle	UBERON:0002084	79.58	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-7037	yes	888.08
E-ANND-3	yes	10.10

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ITGB8, SMAD2, SMAD3, SP1, SP3

Literature-anchored findings (GeneRIF, showing 26)

• Major transcription start site mapped. A core promoter [nt (-)127-(+)25], a potential silencer region [nt (-)400-(-)127] and a potential enhancer region [nt (-)1519-(-)400] identified as important for alpha11 transcription in mesenchymal cells. (PMID:12392762)
• the GFOGER sequence in fibrillar collagens is a common recognition motif used by integrins, particularly alpha11beta1 (PMID:12496264)
• A new interferon stimulated gene. (Integrin alpha 11) (PMID:16697656)
• Through interaction between matrix collagen and stromal fibroblasts, integrin alpha 11 stimulates cancer cell growth. (PMID:17600088)
• analysis of a prokaryotic Scl1 collagen sequence motif that mediates binding to human collagen receptors, integrins alpha2beta1 and alpha11beta1 (PMID:18990704)
• is a major collagen receptor on human periodontal ligament cells [and plays] a role in collagen lattice remodeling [ITGA11B1] (PMID:19641149)
• Data show that the 3 kb alpha11 promoter contains most of the regulatory elements that direct ectomesenchymal and mesodermal fibroblast-specific expression. (PMID:19913614)
• The disturbance of alpha11beta1 mediated interactions to collagen I results in a tremendous reduction of hMSC numbers owing to mitochondrial leakage accompanied by Bcl-2-associated X protein upregulation. (PMID:21796158)
• Interactions between alpha11 integrins and the Smad-dependent TGF-beta2 signalling may contribute to the formation of pro-fibrotic myofibroblasts and the development of a fibrotic interstitium in diabetic cardiomyopathy. (PMID:22869616)
• Myometrium and uterine fibroids express ITGA11. (PMID:24520080)
• glycated collagen in the cardiac interstitium triggers an autocrine TGF-beta2 signaling pathway that stimulates alpha11 integrin expression through Smad2/3 binding elements in the alpha11 integrin promoter (PMID:24962729)
• FGF2 may be redirecting fibroblasts towards an anti-fibrotic phenotype during wound healing by overriding TGFb1 mediated ITGA11 expression. (PMID:26403263)
• Using MDR and RF, the overall best classifier of lung cancer status were SNPs rs1799732 (DRD2), rs5744256 (IL-18), rs2306022 (ITGA11) with training accuracy of 0.6592 and a testing accuracy of 0.6572 and a cross-validation consistency of 10/10 with permutation testing P<0.0001 (PMID:27121382)
• ITGA11 is a highly promising target that is selectively overexpressed in myofibroblasts during fibrotic diseases and regulates myofibroblast differentiation and key phenotypic characteristics. (PMID:29147013)
• By employing co-immunoprecipitation and confocal microscopy analysis we showed that integrin alpha11beta1 and protein disulfide isomerase (PDI) create complexes bounded by disulfide bonds. Using surface plasmon resonance we provide biochemical evidence that PDI can interact directly with integrin subunit alpha11. (PMID:29203246)
• Data show that integrin alpha-11 (integrin alpha11) is a physiologically important receptor for Osteolectin, mediating its effect on osteogenesis. (PMID:30632962)
• this study presents ITGA11 as an interesting stromal therapeutic target that plays a crucial role in the regulation of the differentiation of Pancreatic stellate cells into cancer-associated fibroblasts and paracrine effects. (PMID:30808244)
• integrin alpha11 pro-invasive activity relies on its ability to interact with PDGFRbeta in a ligand-dependent manner and to promote its downstream JNK activation, leading to the production of tenascin C, a pro-invasive matricellular protein. (PMID:31287804)
• Integrin alpha11 cytoplasmic tail is required for FAK activation to initiate 3D cell invasion and ERK-mediated cell proliferation. (PMID:31653900)
• ITGA11 expression may be a predictor of poor prognosis in patients with surgically resected NSCLC. (PMID:31778288)
• p75NTR optimizes the osteogenic potential of human periodontal ligament stem cells by up-regulating alpha1 integrin expression. (PMID:32424966)
• Long noncoding RNA FEZF1AS1 facilitates nonsmall cell lung cancer progression via the ITGA11/miR516b5p axis. (PMID:33174014)
• Cancer-associated fibroblast migration in non-small cell lung cancers is modulated by increased integrin alpha11 expression. (PMID:33682233)
• Inhibition of integrin subunit alpha 11 restrains gastric cancer progression through phosphatidylinositol 3-kinase/Akt pathway. (PMID:34802381)
• Osteosarcoma Cells Secrete CXCL14 That Activates Integrin alpha11beta1 on Fibroblasts to Form a Lung Metastatic Niche. (PMID:38295227)
• PDGFRalpha[+]ITGA11[+] fibroblasts foster early-stage cancer lymphovascular invasion and lymphatic metastasis via ITGA11-SELE interplay. (PMID:38428409)

Cross-species orthologs

9 orthologs

Organism	Symbol	Gene ID
danio_rerio	itga11b	ENSDARG00000007950
danio_rerio	itga11a	ENSDARG00000036086
mus_musculus	Itga11	ENSMUSG00000032243
rattus_norvegicus	Itga11	ENSRNOG00000006723
drosophila_melanogaster	if	FBGN0001250
drosophila_melanogaster	ItgaPS4	FBGN0034005
drosophila_melanogaster	ItgaPS5	FBGN0034880
drosophila_melanogaster	scb	FBGN0286785
caenorhabditis_elegans		WBGENE00003929

Paralogs (17): ITGAL (ENSG00000005844), ITGA3 (ENSG00000005884), ITGA2B (ENSG00000005961), ITGA8 (ENSG00000077943), ITGAE (ENSG00000083457), ITGA6 (ENSG00000091409), ITGA4 (ENSG00000115232), ITGA7 (ENSG00000135424), ITGAV (ENSG00000138448), ITGAX (ENSG00000140678), ITGA10 (ENSG00000143127), ITGA9 (ENSG00000144668), ITGAD (ENSG00000156886), ITGA5 (ENSG00000161638), ITGA2 (ENSG00000164171), ITGAM (ENSG00000169896), ITGA1 (ENSG00000213949)

Protein

Protein identifiers

Integrin alpha-11 — Q9UKX5 (reviewed: Q9UKX5)

All UniProt accessions (1): Q9UKX5

UniProt curated annotations — full annotation on UniProt →

Function. Integrin alpha-11/beta-1 is a receptor for collagen.

Subunit / interactions. Heterodimer of an alpha and a beta subunit. Alpha-11 associates with beta-1. Interacts with RAB21.

Subcellular location. Membrane.

Tissue specificity. According to PubMed:10464311, highest levels of expression in uterus and heart, intermediate levels in skeletal muscle and intermediate to low levels in pancreas, kidney and placenta. According to PubMed:10486209, also found in brain, colon, lung, small intestine, stomach, testis, salivary glands, thyroid glands and prostate. Very low levels in peripheral blood lymphocytes, fetal brain and fetal liver.

Domain organisation. The integrin I-domain (insert) is a VWFA domain. Integrins with I-domains do not undergo protease cleavage.

Similarity. Belongs to the integrin alpha chain family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9UKX5-1	1	yes
Q9UKX5-2	2

RefSeq proteins (1): NP_001004439* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000413	Integrin_alpha	Family
IPR002035	VWF_A	Domain
IPR013517	FG-GAP	Repeat
IPR013519	Int_alpha_beta-p	Repeat
IPR013649	Integrin_alpha_Ig-like_1	Domain
IPR028994	Integrin_alpha_N	Homologous_superfamily
IPR032695	Integrin_dom_sf	Homologous_superfamily
IPR036465	vWFA_dom_sf	Homologous_superfamily
IPR048285	Integrin_alpha_Ig-like_2	Domain

Pfam: PF00092, PF01839, PF08441, PF20805

UniProt features (57 total): glycosylation site 16, binding site 12, repeat 7, disulfide bond 7, sequence variant 7, topological domain 2, signal peptide 1, chain 1, transmembrane region 1, splice variant 1, mutagenesis site 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UKX5-F1	85.13	0.47

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (12): 488; 490; 492; 496; 551; 553; 555; 559; 613; 615; 617; 621

Disulfide bonds (7): 76–83, 121–139, 129–159, 659–668, 674–729, 781–787, 881–893

Glycosylation sites (16): 82, 95, 291, 331, 358, 449, 462, 528, 642, 694, 857, 894, 973, 1031, 1039, 1059

Mutagenesis-validated functional residues (1):

Position	Phenotype
1170	no effect on rab21-binding.

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-216083	Integrin cell surface interactions
R-HSA-1474244	Extracellular matrix organization

MSigDB gene sets: 117 (showing top): RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, GOCC_CELL_SURFACE, GOBP_OSTEOBLAST_DIFFERENTIATION, GOBP_CELL_CELL_ADHESION, CEBP_Q2, PID_CXCR4_PATHWAY, GOBP_MUSCLE_STRUCTURE_DEVELOPMENT, GOBP_OSSIFICATION, AFP1_Q6, WANG_CISPLATIN_RESPONSE_AND_XPC_DN, GOBP_SUBSTRATE_DEPENDENT_CELL_MIGRATION, chr15q23, GOBP_CELL_ADHESION_MEDIATED_BY_INTEGRIN, RGAGGAARY_PU1_Q6, GOBP_CELL_SUBSTRATE_ADHESION

GO Biological Process (9): osteoblast differentiation (GO:0001649), substrate-dependent cell migration (GO:0006929), cell adhesion (GO:0007155), cell-matrix adhesion (GO:0007160), integrin-mediated signaling pathway (GO:0007229), muscle organ development (GO:0007517), cell adhesion mediated by integrin (GO:0033627), collagen-activated signaling pathway (GO:0038065), cell-cell adhesion (GO:0098609)

GO Molecular Function (5): collagen binding (GO:0005518), signaling receptor activity (GO:0038023), collagen receptor activity (GO:0038064), metal ion binding (GO:0046872), collagen binding involved in cell-matrix adhesion (GO:0098639)

GO Cellular Component (6): plasma membrane (GO:0005886), focal adhesion (GO:0005925), integrin complex (GO:0008305), cell surface (GO:0009986), membrane (GO:0016020), integrin alpha11-beta1 complex (GO:0034681)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Extracellular matrix organization	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell surface receptor signaling pathway	2
cell adhesion	2
collagen binding	2
cellular anatomical structure	2
ossification	1
cell differentiation	1
cell migration	1
cellular process	1
cell-substrate adhesion	1
animal organ development	1
muscle structure development	1
protein-containing complex binding	1
molecular transducer activity	1
transmembrane signaling receptor activity	1
collagen-activated signaling pathway	1
cation binding	1
cell-matrix adhesion	1
cell-matrix adhesion mediator activity	1
membrane	1
cell periphery	1
cell-substrate junction	1
protein complex involved in cell adhesion	1
plasma membrane signaling receptor complex	1
integrin complex	1

Protein interactions and networks

STRING

1040 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ITGA11	CORO2B	Q9UQ03	834
ITGA11	TLE3	Q04726	829
ITGA11	ITGB1	P05556	797
ITGA11	COL1A2	P02464	765
ITGA11	ITGB5	P18084	699
ITGA11	KIF23	Q02241	669
ITGA11	ITGB8	P26012	658
ITGA11	ITGB3	P05106	653
ITGA11	COL3A1	P02461	643
ITGA11	COL5A1	P20908	624
ITGA11	FN1	P02751	606
ITGA11	COL6A1	P12109	602
ITGA11	COL1A1	P02452	597
ITGA11	PDGFRB	P09619	589
ITGA11	COL4A1	P02462	588

IntAct

4 interactions, top by confidence:

A	B	Type	Score
ITGA11	Rab21	psi-mi:“MI:0915”(physical association)	0.370
ITGA11	Fabp3	psi-mi:“MI:0915”(physical association)	0.370
IQCB1	PCP4L1	psi-mi:“MI:0914”(association)	0.350

BioGRID (5): ITGA11 (Proximity Label-MS), ITGA11 (Cross-Linking-MS (XL-MS)), ITGA11 (Cross-Linking-MS (XL-MS)), ITGA11 (Affinity Capture-MS), ITGA11 (Affinity Capture-MS)

ESM2 similar proteins: A2ARA8, B0S5N4, B8JK39, F1MMS9, O08665, P05555, P06756, P08514, P08648, P11215, P11688, P13612, P17301, P17852, P18564, P20701, P23229, P24063, P26006, P26007, P26008, P26009, P38570, P43406, P53708, P53710, P53711, P61622, P61625, P80746, Q00651, Q06274, Q13683, Q13797, Q60677, Q61738, Q61739, Q62469, Q62470, Q63258

Diamond homologs: A2AX52, A6H584, A6NMZ7, A6QLN9, A8TX70, E7FF10, O00339, O08746, O42401, O75578, O89029, P05099, P05555, P11215, P12111, P15989, P20701, P20702, P34576, P51942, P61625, Q02388, Q13349, Q21281, Q21540, Q28902, Q3V0T4, Q63870, Q642A6, Q6PCB0, Q6UXI7, Q8C6K9, Q8NFW1, Q8R2Z5, Q90615, Q91145, Q923P0, Q95LI2, Q96P44, Q9P218

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
SP1	“up-regulates quantity by expression”	ITGA11
SP3	“up-regulates quantity by expression”	ITGA11
ETS1	“up-regulates quantity by expression”	ITGA11
ITGA11	“form complex”	“A11/b1 integrin”	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

233 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	192
Likely benign	13
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

4814 predictions. Top by Δscore:

Variant	Effect	Δscore
15:68307342:GCTCA:G	donor_loss	1.0000
15:68307343:CTCAC:C	donor_loss	1.0000
15:68307344:TCA:T	donor_loss	1.0000
15:68307345:CACCT:C	donor_loss	1.0000
15:68307439:TTGAG:T	acceptor_gain	1.0000
15:68307440:TGAG:T	acceptor_gain	1.0000
15:68307441:GAG:G	acceptor_gain	1.0000
15:68307443:GCTGT:G	acceptor_loss	1.0000
15:68307444:C:CC	acceptor_gain	1.0000
15:68307446:G:C	acceptor_gain	1.0000
15:68307446:G:GC	acceptor_gain	1.0000
15:68307581:CTTA:C	donor_gain	1.0000
15:68307582:TTA:T	donor_loss	1.0000
15:68307583:TAC:T	donor_loss	1.0000
15:68307584:A:AC	donor_gain	1.0000
15:68307584:ACTG:A	donor_gain	1.0000
15:68307585:C:CA	donor_gain	1.0000
15:68307585:CT:C	donor_gain	1.0000
15:68307585:CTG:C	donor_gain	1.0000
15:68307585:CTGC:C	donor_gain	1.0000
15:68307585:CTGCT:C	donor_gain	1.0000
15:68307692:TGATT:T	acceptor_gain	1.0000
15:68307693:GATT:G	acceptor_gain	1.0000
15:68307694:ATT:A	acceptor_gain	1.0000
15:68307695:TT:T	acceptor_gain	1.0000
15:68307697:C:CC	acceptor_gain	1.0000
15:68307698:T:G	acceptor_loss	1.0000
15:68310986:ACACT:A	donor_loss	1.0000
15:68310987:CACT:C	donor_loss	1.0000
15:68310988:ACTCA:A	donor_loss	1.0000

AlphaMissense

7869 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:68339500:C:A	G426W	1.000
15:68339601:C:T	G392E	1.000
15:68339606:C:A	W390C	1.000
15:68339606:C:G	W390C	1.000
15:68339608:A:G	W390R	1.000
15:68339608:A:T	W390R	1.000
15:68350664:A:G	L338S	1.000
15:68350715:G:T	A321D	1.000
15:68351259:G:T	A298D	1.000
15:68351337:C:T	G272E	1.000
15:68351338:C:A	G272W	1.000
15:68351339:A:C	D271E	1.000
15:68351339:A:T	D271E	1.000
15:68351340:T:A	D271V	1.000
15:68351341:C:G	D271H	1.000
15:68358524:C:A	W178C	1.000
15:68358524:C:G	W178C	1.000
15:68358526:A:G	W178R	1.000
15:68358526:A:T	W178R	1.000
15:68358543:G:A	S172F	1.000
15:68358544:A:G	S172P	1.000
15:68358549:T:A	D170V	1.000
15:68361647:A:G	C139R	1.000
15:68361652:C:T	G137E	1.000
15:68361653:C:A	G137W	1.000
15:68361687:C:A	W125C	1.000
15:68361687:C:G	W125C	1.000
15:68361699:G:C	C121W	1.000
15:68361701:A:G	C121R	1.000
15:68332462:C:T	G481E	0.999

dbSNP variants (sampled 300 via entrez): RS1000004062 (15:68301020 G>A), RS1000017215 (15:68359744 A>G), RS1000035229 (15:68301307 G>C), RS1000050345 (15:68382356 C>T), RS1000082629 (15:68354449 C>T), RS1000082919 (15:68379391 G>A,T), RS1000085519 (15:68318693 G>A), RS1000106515 (15:68433220 G>C), RS1000111623 (15:68316482 A>G), RS1000144836 (15:68323898 C>A,T), RS1000152570 (15:68379618 G>A), RS1000153489 (15:68376981 T>C,G), RS1000175952 (15:68306516 C>G,T), RS1000176702 (15:68342325 C>T), RS1000183599 (15:68308886 G>A)

Disease associations

OMIM: gene MIM:604789 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST000246_9	Attention deficit hyperactivity disorder	1.000000e-07
GCST001850_12	Major depressive disorder	9.000000e-07
GCST001850_6	Major depressive disorder	3.000000e-07
GCST003670_1	Systolic blood pressure	3.000000e-08
GCST003670_10	Systolic blood pressure	1.000000e-07
GCST004858_20	Dupuytren’s disease	9.000000e-11
GCST008763_1	Perceived intensity of fructose	3.000000e-06
GCST012227_295	Hip circumference adjusted for BMI	2.000000e-09
GCST012229_222	Hip index	5.000000e-09

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0006335	systolic blood pressure
EFO:0004229	Dupuytren Contracture
EFO:0008039	BMI-adjusted hip circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5883 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — Integrins

CTD chemical–gene interactions

53 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	increases expression, increases methylation	2
sodium arsenite	decreases expression, increases expression	2
Acetaminophen	decreases expression, increases expression	2
Benzo(a)pyrene	decreases methylation, increases expression, increases methylation	2
Copper	affects binding, increases expression	2
Dexamethasone	decreases expression, affects cotreatment	2
Valproic Acid	increases expression, increases methylation	2
Aflatoxin B1	affects methylation, increases expression	2
aristolochic acid I	increases expression	1
bisphenol F	affects cotreatment, increases methylation	1
methyleugenol	increases expression	1
propionaldehyde	decreases expression	1
cinnamaldehyde	increases expression	1
benzo(e)pyrene	decreases methylation	1
potassium chromate(VI)	decreases expression	1
rutecarpine	increases expression	1
S-(1,2-dichlorovinyl)cysteine	decreases expression, affects cotreatment	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
CD 437	decreases expression	1
entinostat	increases expression	1
3-(4’-hydroxy-3’-adamantylbiphenyl-4-yl)acrylic acid	decreases expression	1
2,2’,4,4’,5-brominated diphenyl ether	increases expression	1
abrine	decreases expression	1
quinocetone	decreases expression	1
jinfukang	affects cotreatment, decreases expression	1
Dasatinib	increases expression	1
Sunitinib	decreases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Bleomycin	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL905726	Binding	Inhibition of integrin alpha-11 binding to collagen 1 at 50 uM	Small molecule designed to target metal binding site in the alpha2I domain inhibits integrin function. — J Med Chem

Cellosaurus cell lines

3 cell lines: 2 cancer cell line, 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A0NQ	C2C12-hITGA11	Spontaneously immortalized cell line	Female
CVCL_B1UU	Abcam HeLa ITGA11 KO	Cancer cell line	Female
CVCL_E0FF	Ubigene HeLa ITGA11 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.